hema.to
Key Facts
Invested since | 2023 |
Based in | Bavaria |
About the company

hema.to is an easy-to-use software for clinical decision support for blood cancer from cytometry data using AI. hema.to makes the diagnostic workflow both faster and better, helping both diagnosticians as well as patients. hema.to is a CE-IVD, FDA registered and already in routine use by leading hematology laboratories. Founded in 2021, hema.to’s mission is to make clinical analysis of cytometry data completely objective, to enable doctors to personalize treatment to their patient’s unique immune system.
Do you want to
know more about this company?
hema.to in the news

German digital medtech startup hema.to receives €3.6 million investment from LUMO Labs and Bayern Kapital for AI-based blood data analysis.
